04:56 PM EDT, 03/17/2026 (MT Newswires) -- Myriad Genetics ( MYGN ) said Tuesday the US Food and Drug Administration has approved the MyChoice test as the companion diagnostic for GSK's (GSK) Zejula for patients with ovarian cancer.

MyChoice CDx is the only FDA-approved companion test in the US to identify people with homologous recombination deficiency-positive status eligible for treatment with Zejula, Myriad said.

Myriad shares were up nearly 3% in after-hours activity.